Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardio-Protective of Effect of Saxagliptin and Dapagliflozin Combination on Endothelial Progenitor Cells in Patients With Type 2 Diabetes

NCT03660683 is registered in ClinicalTrials.gov with Sabyasachi Sen as lead sponsor.

NCT NCT03660683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03660683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cardio-Protective of Effect of Saxagliptin and Dapagliflozin Combination on Endothelial Progenitor Cells in Patients With Type 2 Diabetes
Lead sponsor
Sabyasachi Sen
Phase
Phase 4
Overall status
Terminated
Start date
October 22, 2018
Completion date
December 10, 2021
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, diabetes mellitus, type 2